Source: Lung Cancer. Unidade: IQ
Subjects: NEOPLASIAS PULMONARES, ANTINEOPLÁSICOS
ABNT
LOBO, Tatiana Correa Carneiro et al. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: a potential anti-angiogenic therapeutic target. Lung Cancer, v. 130, p. 169-178, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.lungcan.2019.02.027. Acesso em: 05 set. 2024.APA
Lobo, T. C. C., Scalabrini, L. C., Magalhães, L. da S., Cardeal, L. B., Rodrigues, F. S., Santos, E. O. dos, et al. (2019). IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: a potential anti-angiogenic therapeutic target. Lung Cancer, 130, 169-178. doi:10.1016/j.lungcan.2019.02.027NLM
Lobo TCC, Scalabrini LC, Magalhães L da S, Cardeal LB, Rodrigues FS, Santos EO dos, Baldwin AS, Levantini E, Giordano RJ, Bassères DS. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: a potential anti-angiogenic therapeutic target [Internet]. Lung Cancer. 2019 ; 130 169-178.[citado 2024 set. 05 ] Available from: https://doi.org/10.1016/j.lungcan.2019.02.027Vancouver
Lobo TCC, Scalabrini LC, Magalhães L da S, Cardeal LB, Rodrigues FS, Santos EO dos, Baldwin AS, Levantini E, Giordano RJ, Bassères DS. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: a potential anti-angiogenic therapeutic target [Internet]. Lung Cancer. 2019 ; 130 169-178.[citado 2024 set. 05 ] Available from: https://doi.org/10.1016/j.lungcan.2019.02.027